[Biochemical markers for Alzheimer disease].
It is estimated that approximately 40,000 people in Denmark suffer from Alzheimer's disease (AD), a neurodegenerative dementia. Symptomatic treatment now exists which can temporarily inhibit the loss of brain function. Unfortunately, AD is difficult to diagnose, especially early in the disease course, and a definite diagnosis is possible only post-mortem. To develop improved diagnostic methods, several biomarkers have been examined for their ability to differentiate AD from normal aging and other dementias. Their measurement in blood samples has not yet been developed, but analyses may now be routinely performed using cerebrospinal fluid (CSF). The CSF biomarkers include amyloid-beta 1-42 (Abeta1-42), which is decreased in AD patients, as well as total tau (t-tau) and hyperphosphorylated tau (p-tau), which are elevated. While a decreased Abeta1-42 level in CSF has no independent value in the diagnostic differentiation, t-tau and p-tau add more specificity to the differentiation of AD from other dementias while retaining a reasonable degree of sensitivity.
Czarna
Justyna Maria
JM
Statens Serum Institut, Autoimmunafdelingen, og H:S Rigshospitalet, Hukommelsesklinikken, Neurologisk Afdeling.
Waldemar
Gunhild
G
Heegaard
Niels H H
NH
D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid; D016564:Amyloid beta-Protein Precursor / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000134:cerebrospinal fluid*; D002540:Cerebral Cortex / Q000473:pathology; D003704:Dementia / Q000134:cerebrospinal fluid; D003937:Diagnosis, Differential; D006801:Humans; D008875:Middle Aged; D012680:Sensitivity and Specificity; D016875:tau Proteins / Q000134:cerebrospinal fluid
D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D015415:Biomarkers; D016875:tau Proteins